- Home
- LPSN vs ANEB Comparison
LPSN vs ANEB Comparison
Compare LPSN & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPSN | ANEB |
|---|---|---|
| Founded | 1995 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.5M | 46.0M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LPSN | ANEB |
|---|---|---|
| Price | $3.93 | $0.99 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 220.6K | 126.1K |
| Earning Date | 11-10-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,660,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.87 | $0.90 |
| 52 Week High | $31.20 | $3.42 |
Technical Indicators
Market Signals| Indicator | LPSN | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 35.25 | 17.26 |
| Support Level | $3.91 | $0.91 |
| Resistance Level | $4.18 | $1.25 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | -0.08 | -0.12 |
| Stochastic Oscillator | 1.85 | 5.00 |
Price Performance
Historical ComparisonAbout LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.